- CRG-023 is a CD19-, CD20-, CD22-targeting tri-specific CAR T product candidate designed with the goal of providing more patients with a broad range of B-cell malignancies with durable responses by ...

NOTE. The Involvement row lists measurable sites of HCL/HCLv outside the bone marrow, which also constituted indications for treatment. Mutations were determined by TSO500 NGS of 523 genes. VAF are ...

Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study ...